MBX Biosciences, Inc. (MBX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 23.66M USD | Liabilities, Current |
| Cash and equivalents | 54.12M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 364.46M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $23.66M | $54.12M | $364.46M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $14.57M | $45.21M | $394.76M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $15.49M | $75.29M | $298.42M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $12.06M | $223.13M | $168.55M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $11.76M | $39.78M | $185.13M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $10.48M | $29.90M | $210.88M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $11.05M | $49.35M | $212.80M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $10.92M | $132.87M | $144.20M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $3.93M | $30.52M | $50.15M | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |